Job Announcement: Government Affairs Manager

The HIV+Hepatitis Policy Institute is seeking a Government Affairs Manager to advocate for our policy goals to end the HIV and hepatitis epidemics and increase access and affordability of health care with a focus on prescription drugs. Please email a cover letter and resume to HR@HIVHep.org with your name in the subject line.
See the job description

House Proposes to Gut Ending HIV Programs—Again

Instead of providing new investments in ending HIV by increasing funding for testing, prevention programs, such as PrEP, and life-saving care and treatment, House Republicans are again choosing to go through a worthless exercise of cutting programs that the American people depend on and will never pass.
See the press release

New CDC HIV Data Demonstrates the Impact of Flat Funding

Federal funding for CDC HIV prevention and the Ryan White HIV/AIDS care and treatment program, along with other critical programs, has remained flat for years. Without significant increases for care and treatment, and prevention programs, including those for PrEP, sadly we will continue to experience only small drops in the number of new diagnoses, and racial and ethnic disparities will persist. As a nation, we can and must do better.
See the press release

Biden Administration Strengthens Patient Protections in Accessing Prescription Drugs

We applaud the Biden administration’s strengthening of the nondiscrimination regulation in order to ensure that patients, particularly those who rely on prescription drugs, are better protected against the discriminatory practices of some insurers and PBMs.
See the press release

Federal Government Refuses to Enforce Copay Assistance Court Victory, But Moves to Stop Scheme of Classifying Drugs as “Non-Essential Health Benefits”

As part of the final 2025 NBPP rule, the federal government completely ignored the D.C. District Court decision that struck down the rule allowing insurers not to count copay assistance for prescription drugs as part of patient cost-sharing. However, they do move to stop a new scheme that insurers and employers are engaged in: classifying certain drugs as “non-essential health benefits.”
See the press release

Who We Are

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Key Issues

Causes We Care About, and So Should You!

HIV

Promote necessary funding, programs, and policies to end the HIV epidemic in the United States

HEPATITIS

Promote necessary funding, programs, and policies to end viral hepatitis in the United States

HEALTHCARE ACCESS

Promote necessary funding, programs, and policies to end viral hepatitis in the United States

Learn More

Facebook posts by @HIV+Hep

HIV and Hepatitis Policy Institute

2 weeks ago

HIV and Hepatitis Policy Institute
The HIV and Hepatitis Policy Institute is seeking a Government Affairs Manager to advocate for our policy goals to end the #HIV & #hepatitis epidemics & to increase healthcare access & affordability, with a focus on #Rx: bit.ly/3Avqbtz ... See MoreSee Less

Photo

View on Facebook
· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

HIV and Hepatitis Policy Institute

2 weeks ago

HIV and Hepatitis Policy Institute
Job Announcement: The HIV and Hepatitis Policy Institute is seeking a Government Affairs Manager to advocate for our policy goals to end the #HIV & #hepatitis epidemics & to increase healthcare access & affordability, with a focus on #Rx: bit.ly/3W3Wzvt ... See MoreSee Less

Photo

View on Facebook
· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

HIV and Hepatitis Policy Institute

3 weeks ago

HIV and Hepatitis Policy Institute
The HIV and Hepatitis Policy Institute’s Carl Schmid will participate in a webinar on how state Prescription Drug Affordability Boards (PDABs) may impact #patient #Rx affordability and access on Mon., 8/19 at 3:30pm EDT. To register click here: bit.ly/4dcHduB ... See MoreSee Less

Photo

View on Facebook
· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Tweets by @HIV+Hep

Pin It on Pinterest